Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERIS: EGFR-Mutated Lung Cancer Randomized Study
2024-518172-31-01Phase 3Authorised
- Sponsor
- Region Skåne
- Start
- Dec 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in EGFR-mutated non-small cell lung cancer comparing First-line dacomitinib, First-line afatinib and First-line osimertinib (3 arms). Primary endpoint: Progression-free survival. Planned start Dec 2024; status: authorised.
02
Drugs
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on 2024-518172-31-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518172-31-01.